| 0.3 0.3 (100%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.16 | 1-year : | 0.18 |
| Resists | First : | 0.13 | Second : | 0.16 |
| Pivot price | 0.08  |
|||
| Supports | First : | 0.09 | Second : | 0.06 |
| MAs | MA(5) : | 0.09 |
MA(20) : | 0.08 |
| MA(100) : | 0.08 |
MA(250) : | 0.3  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 43.9 |
D(3) : | 34.5 |
| RSI | RSI(14): 55.3 | |||
| 52-week | High : | 1.34 | Low : | 0.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CYTO ] has closed below upper band by 19.6%. Bollinger Bands are 29.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.1 - 0.1 | 0.1 - 0.1 |
| Low: | 0.1 - 0.1 | 0.1 - 0.1 |
| Close: | 0.1 - 0.1 | 0.1 - 0.1 |
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Sat, 25 Jan 2025
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries - accessnewswire.com
Fri, 20 Dec 2024
Altamira Therapeutics Ltd. to Transition from Nasdaq to OTCQB Following Delisting Decision | CYTO Stock News - Quiver Quantitative
Fri, 20 Dec 2024
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets - Yahoo Finance
Mon, 23 Sep 2024
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia - 팜뉴스
Mon, 12 Aug 2024
Altamira Therapeutics Announces Significant Enhancement of - GlobeNewswire
Thu, 23 May 2024
What's Going On With Altamira Therapeutics Stock? - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 31 (K) |
| EPS | 1.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -57.2 % |
| Return on Equity (ttm) | -368.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|